{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:04:21Z","timestamp":1791896661802,"version":"4.3.4"},"reference-count":105,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The risk of cardiovascular events increases considerably after an acute coronary syndrome (ACS), particularly in the first few months. Dual antiplatelet therapy represents the mainstay of secondary prevention during this period, but is associated with a not-negligible risk of bleeding which, among other factors, is influenced by the platelet count. Thrombocytopenic patients may experience an ACS, and several patients with ACSs develop thrombocytopenia during hospitalization: the management of antithrombotic therapy in this setting represents a challenge. Here, we review the available evidence on the use of antithrombotic therapy in patients with low platelet counts after an ACS.<\/jats:p>","DOI":"10.3390\/jcm14030838","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T08:57:48Z","timestamp":1738054668000},"page":"838","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antiplatelet Therapy in Low-Platelet-Count Patients After Percutaneous Coronary Intervention for Acute Coronary Syndromes"],"prefix":"10.3390","volume":"14","author":[{"given":"Francesco","family":"Paciullo","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, Via Olgettina 58, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gresele","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Perugia, Strada Vicinale Via Delle Corse, 06132 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11883-017-0654-1","article-title":"New-Generation Coronary Stents: Current Data and Future Directions","volume":"19","author":"Kalra","year":"2017","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e009565","DOI":"10.1161\/CIRCINTERVENTIONS.120.009565","article-title":"One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention with Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients","volume":"13","author":"Kandzari","year":"2020","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5144\/0256-4947.2016.17","article-title":"Incidence and prognosis of stent thrombosis following percutaneous coronary intervention in Middle Eastern patients: The First Jordanian Percutaneous Coronary Intervention Registry (JoPCR1)","volume":"36","author":"Saleh","year":"2016","journal-title":"Ann. Saudi Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1001\/jama.2021.0716","article-title":"Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review","volume":"325","author":"Kamran","year":"2021","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"717","DOI":"10.4244\/EIJ-D-17-00468","article-title":"State of the art: Duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation\u2014Past, present and future perspectives","volume":"13","author":"Gargiulo","year":"2017","journal-title":"EuroIntervention"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e008226","DOI":"10.1161\/CIRCINTERVENTIONS.119.008226","article-title":"Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry","volume":"13","author":"Sorrentino","year":"2020","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/jth.14227","article-title":"Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults","volume":"16","author":"Mahevas","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/jth.14446","article-title":"Cardiovascular and bleeding outcomes in a population-based cohort of patients with chronic immune thrombocytopenia","volume":"17","author":"Adelborg","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.amjcard.2008.08.055","article-title":"Thrombocytopenia in patients with an acute coronary syndrome (from the Global Registry of Acute Coronary Events [GRACE])","volume":"103","author":"Gore","year":"2009","journal-title":"Am. J. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes","volume":"381","author":"Schupke","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e750","DOI":"10.1097\/HS9.0000000000000750","article-title":"EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients with Cancer","volume":"6","author":"Falanga","year":"2022","journal-title":"Hemasphere"},{"key":"ref_13","first-page":"349","article-title":"Antiplatelet agents in clinical practice and their haemorrhagic risk","volume":"11","author":"Gresele","year":"2013","journal-title":"Blood Transfus."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2165\/00002512-200320090-00006","article-title":"NSAID and aspirin use by the elderly in general practice: Effect on gastrointestinal symptoms and therapies","volume":"20","author":"Pilotto","year":"2003","journal-title":"Drugs Aging"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.7326\/M24-0427","article-title":"Aspirin Use Prevalence for Cardiovascular Disease Prevention Among U.S. Adults From 2012 to 2021","volume":"177","author":"Gupta","year":"2024","journal-title":"Ann. Intern. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/j.jacc.2019.03.501","article-title":"Aspirin for Primary Prevention of Cardiovascular Events","volume":"73","author":"Abdelaziz","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1093\/eurheartj\/ehac416","article-title":"Aspirin: 1A @ 125","volume":"43","author":"Patrono","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1177\/1747493016677989","article-title":"Intravenous administration of tirofiban versus loading dose of oral clopidogrel for preventing thromboembolism in stent-assisted coiling of intracranial aneurysms","volume":"12","author":"Li","year":"2017","journal-title":"Int. J. Stroke"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Gresele, P., and Momi, S. (2022). Novel approaches to antiplatelet therapy. Biochem. Pharmacol., 206.","DOI":"10.1016\/j.bcp.2022.115297"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e2449017","DOI":"10.1001\/jamanetworkopen.2024.49017","article-title":"Risk of Intracranial Hemorrhage Associated with Direct Oral Anticoagulation vs Antiplatelet Therapy: A Systematic Review and Meta-Analysis","volume":"7","author":"Coyle","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ajh.10451","article-title":"Risk of bleeding complications with antiplatelet agents: Meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials","volume":"75","author":"Serebruany","year":"2004","journal-title":"Am. J. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.amjcard.2023.08.117","article-title":"Ticagrelor Versus Prasugrel in Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis","volume":"207","author":"Shah","year":"2023","journal-title":"Am. J. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.amjcard.2015.04.054","article-title":"Meta-Analysis of Randomized Controlled Trials Comparing Risk of Major Adverse Cardiac Events and Bleeding in Patients with Prasugrel Versus Clopidogrel","volume":"116","author":"Chen","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamacardio.2024.0534","article-title":"Extended Clopidogrel Monotherapy vs DAPT in Patients with Acute Coronary Syndromes at High Ischemic and Bleeding Risk: The OPT-BIRISK Randomized Clinical Trial","volume":"9","author":"Li","year":"2024","journal-title":"JAMA Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/j.1365-2036.2006.03077.x","article-title":"Review article: Gastrointestinal bleeding with low-dose aspirin\u2014What\u2019s the risk?","volume":"24","author":"Laine","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.jacc.2021.07.048","article-title":"Intracranial Hemorrhage During Dual Antiplatelet Therapy: JACC Review Topic of the Week","volume":"78","author":"Ha","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Antithrombotic Trialists\u2019 (ATT) Collaboration, Baigent, C., Blackwell, L., Collins, R., Emberson, J., Godwin, J., Peto, R., Buring, J., Hennekens, C., and Kearney, P. (2009). Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet, 373, 1849\u20131860.","DOI":"10.1016\/S0140-6736(09)60503-1"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/jama.2018.20578","article-title":"Association of Aspirin Use for Primary Prevention with Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis","volume":"321","author":"Zheng","year":"2019","journal-title":"JAMA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1161\/STROKEAHA.118.021789","article-title":"Antiplatelet Therapy, Cerebral Microbleeds, and Intracerebral Hemorrhage: A Meta-Analysis","volume":"49","author":"Qiu","year":"2018","journal-title":"Stroke"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/STROKEAHA.117.016290","article-title":"Association Between Previous Use of Antiplatelet Therapy and Intracerebral Hemorrhage Outcomes","volume":"48","author":"Khan","year":"2017","journal-title":"Stroke"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Gulati, S., Solheim, O., Carlsen, S.M., Oie, L.R., Jensberg, H., Gulati, A.M., Madsbu, M.A., Giannadakis, C., Jakola, A.S., and Salvesen, O. (2018). Risk of intracranial hemorrhage (RICH) in users of oral antithrombotic drugs: Nationwide pharmacoepidemiological study. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0202575"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/MNJY9014","article-title":"Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: The ADAPTT retrospective population-based cohort studies","volume":"27","author":"Harris","year":"2023","journal-title":"Health Technol. Assess."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1056\/NEJMoa0904084","article-title":"Dose of prophylactic platelet transfusions and prevention of hemorrhage","volume":"362","author":"Slichter","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1182\/blood-2017-01-757930","article-title":"Laboratory predictors of bleeding and the effect of platelet and RBC transfusions on bleeding outcomes in the PLADO trial","volume":"130","author":"Uhl","year":"2017","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e034709","DOI":"10.1161\/JAHA.124.034709","article-title":"Abbreviated Versus Standard Dual Antiplatelet Therapy Times After Percutaneous Coronary Intervention in Patients with High Bleeding Risk with Acute Coronary Syndrome: Insights From the SWEDEHEART Registry","volume":"13","author":"Hakansson","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1515\/cclm-2019-0380","article-title":"The role of platelets in bleeding in patients with thrombocytopenia and hematological disease","volume":"57","author":"Vinholt","year":"2019","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM196205032661802","article-title":"The quantitative relation between platelet count and hemorrhage in patients with acute leukemia","volume":"266","author":"Gaydos","year":"1962","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1160\/TH17-06-0387","article-title":"Platelet Function in ITP, Independent of Platelet Count, Is Consistent Over Time and Is Associated with Both Current and Subsequent Bleeding Severity","volume":"118","author":"Frelinger","year":"2018","journal-title":"Thromb. Haemost."},{"key":"ref_41","first-page":"398","article-title":"Percutaneous coronary intervention in elderly patients: Is it beneficial?","volume":"38","author":"Shanmugasundaram","year":"2011","journal-title":"Tex. Heart Inst. J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jcin.2013.04.016","article-title":"An updated bleeding model to predict the risk of post-procedure bleeding among patients undergoing percutaneous coronary intervention: A report using an expanded bleeding definition from the National Cardiovascular Data Registry CathPCI Registry","volume":"6","author":"Rao","year":"2013","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2147\/CIA.S369574","article-title":"Older Adults and Immune Thrombocytopenia: Considerations for the Clinician","volume":"18","author":"Crickx","year":"2023","journal-title":"Clin. Interv. Aging"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1055\/s-0034-1389080","article-title":"Thrombocytopenia in older adults","volume":"40","author":"McMahon","year":"2014","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"100389","DOI":"10.1016\/j.jacadv.2023.100389","article-title":"Assessment and Management of Older Adults Undergoing PCI, Part 1: A JACC: Advances Expert Panel","volume":"2","author":"Nanna","year":"2023","journal-title":"JACC Adv."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S0140-6736(20)30325-1","article-title":"Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): The randomised, open-label, non-inferiority trial","volume":"395","author":"Gimbel","year":"2020","journal-title":"Lancet"},{"key":"ref_47","first-page":"3111840","article-title":"Dual Antiplatelet Therapy in Patients Aged 75 Years and Older with Coronary Artery Disease: A Meta-Analysis and Systematic Review","volume":"2022","author":"Lacy","year":"2022","journal-title":"J. Interv. Cardiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/eurheartj\/ehac706","article-title":"Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: A meta-analysis of randomized trials","volume":"44","author":"Costa","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4330\/wjc.v13.i8.243","article-title":"Shortened dual antiplatelet therapy in contemporary percutaneous coronary intervention era","volume":"13","author":"Han","year":"2021","journal-title":"World J. Cardiol."},{"key":"ref_50","first-page":"8817067","article-title":"Acute Profound Thrombocytopenia Induced by Eptifibatide Causing Diffuse Alveolar Hemorrhage","volume":"2021","author":"Byrd","year":"2021","journal-title":"Case Rep. Crit. Care"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/1522-726X(200008)50:4<426::AID-CCD12>3.0.CO;2-L","article-title":"Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine","volume":"50","author":"Dillon","year":"2000","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM200106213442502","article-title":"Comparison of two platelet glycoprotein IIb\/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization","volume":"344","author":"Topol","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1093\/eurheartj\/ehx531","article-title":"The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: A clinical conundrum","volume":"38","author":"McCarthy","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.cjca.2015.05.020","article-title":"Effect of Baseline Thrombocytopenia on Ischemic Outcomes in Patients with Acute Coronary Syndromes Who Undergo Percutaneous Coronary Intervention","volume":"32","author":"Yadav","year":"2016","journal-title":"Can. J. Cardiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1161\/01.CIR.99.22.2892","article-title":"Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb\/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial experience","volume":"99","author":"McClure","year":"1999","journal-title":"Circulation"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1161\/CIRCULATIONAHA.108.827162","article-title":"Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice","volume":"119","author":"Wang","year":"2009","journal-title":"Circulation"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e005635","DOI":"10.1161\/CIRCINTERVENTIONS.117.005635","article-title":"Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)","volume":"11","author":"Groves","year":"2018","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ahj.2014.04.010","article-title":"Long-term outcomes associated with hospital acquired thrombocytopenia among patients with non-ST-segment elevation acute coronary syndrome","volume":"168","author":"Vora","year":"2014","journal-title":"Am. Heart J."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Gresele, P., Guglielmini, G., Del Pinto, M., Calabro, P., Pignatelli, P., Patti, G., Pengo, V., Antonucci, E., Cirillo, P., and Fierro, T. (2024). Low platelet count at admission has an adverse impact on outcome in patients with acute coronary syndromes: From the START Antiplatelet registry. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-64113-5"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Dutsch, A., Graesser, C., Novacek, S., Krefting, J., Schories, V., Niedermeier, B., Voll, F., Kufner, S., Xhepa, E., and Joner, M. (2024). Baseline Platelet Count Predicts Infarct Size and Mortality after Acute Myocardial Infarction. Hamostaseologie.","DOI":"10.1055\/a-2299-0130"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/bjh.17709","article-title":"Risk factors of hospitalisation for thrombosis in adults with primary immune thrombocytopenia, including disease-specific treatments: A French nationwide cohort study","volume":"195","author":"Lafaurie","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"109109","DOI":"10.1016\/j.thromres.2024.109109","article-title":"The immune thrombocytopenia paradox: Should we be concerned about thrombosis in ITP?","volume":"241","author":"Saldanha","year":"2024","journal-title":"Thromb. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1080\/09537104.2018.1475637","article-title":"Megakaryocyte apoptosis in immune thrombocytopenia","volume":"29","author":"Vrbensky","year":"2018","journal-title":"Platelets"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/bjh.17390","article-title":"Thrombosis in immune thrombocytopenia\u2014Current status and future perspectives","volume":"194","author":"Swan","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1526-0968.2002.00363.x","article-title":"Myocardial infarction\/injury is relatively common at presentation of acute thrombotic thrombocytopenic purpura: The Indiana University experience","volume":"6","author":"McCarthy","year":"2002","journal-title":"Ther. Apher."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Sukumar, S., Mazepa, M.A., and Chaturvedi, S. (2023). Cardiovascular Disease and Stroke in Immune TTP-Challenges and Opportunities. J. Clin. Med., 12.","DOI":"10.3390\/jcm12185961"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1097\/MBC.0000000000000513","article-title":"Acute myocardial infarction as the initial thrombotic event of thrombotic thrombocytopenic purpura","volume":"27","author":"Takimoto","year":"2016","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"8104","DOI":"10.12998\/wjcc.v9.i27.8104","article-title":"Acute myocardial infarction and extensive systemic thrombosis in thrombotic thrombocytopenic purpura: A case report and review of literature","volume":"9","author":"Salaru","year":"2021","journal-title":"World J. Clin. Cases"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e11206","DOI":"10.1097\/MD.0000000000011206","article-title":"Ticagrelor-induced thrombotic thrombocytopenic purpura: A case report and review of the literature","volume":"97","author":"Wang","year":"2018","journal-title":"Medicine"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1055\/s-0032-1328894","article-title":"Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: A 20-year review from the Southern Network on Adverse Reactions (SONAR)","volume":"38","author":"Jacob","year":"2012","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s11239-013-1018-5","article-title":"ST-segment elevation myocardial infarction treated with thrombolytic therapy in a patient with thrombotic thrombocytopenic purpura","volume":"38","author":"Doll","year":"2014","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.thromres.2004.10.009","article-title":"Incidence of heparin-PF4 complex antibody formation and heparin-induced thrombocytopenia in acute coronary syndrome","volume":"115","author":"Matsuo","year":"2005","journal-title":"Thromb. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"646","DOI":"10.4070\/kcj.2012.42.9.646","article-title":"Acute Stent Thrombosis and Heparin Induced Thrombocytopenia in a Patient with ST-Segment Elevation Myocardial Infarction","volume":"42","author":"Shin","year":"2012","journal-title":"Korean Circ. J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1160\/TH12-03-0212","article-title":"Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome","volume":"109","author":"Bontadi","year":"2013","journal-title":"Thromb. Haemost."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.thromres.2008.05.015","article-title":"Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function","volume":"123","author":"Gresele","year":"2009","journal-title":"Thromb. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"SI24","DOI":"10.1093\/rheumatology\/kead571","article-title":"Epidemiology of antiphospholipid syndrome: Macro- and microvascular manifestations","volume":"63","author":"Gaspar","year":"2024","journal-title":"Rheumatology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1177\/0961203309106832","article-title":"The Euro-Phospholipid project: Epidemiology of the antiphospholipid syndrome in Europe","volume":"18","author":"Cervera","year":"2009","journal-title":"Lupus"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1111\/jth.13763","article-title":"Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: A longitudinal study","volume":"15","author":"Hisada","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"103417","DOI":"10.1016\/j.autrev.2023.103417","article-title":"Thrombocytopenia in antiphospholipid syndrome: Is anticoagulation and\/or antiaggregation always required?","volume":"23","author":"Zuily","year":"2024","journal-title":"Autoimmun. Rev."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11926-020-00935-2","article-title":"Management of Non-criteria Manifestations in Antiphospholipid Syndrome","volume":"22","author":"Xourgia","year":"2020","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/jth.15217","article-title":"Monitoring of anticoagulation in thrombotic antiphospholipid syndrome","volume":"19","author":"Cohen","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/ehjcvp\/pvz031","article-title":"Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: A systematic review and meta-analysis","volume":"6","author":"Galli","year":"2020","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"286","DOI":"10.31083\/j.rcm2308286","article-title":"Bleeding Complications in Patients Undergoing Percutaneous Coronary Intervention","volume":"23","author":"Galli","year":"2022","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.jcin.2024.08.022","article-title":"Antithrombotic Therapy in High Bleeding Risk, Part I: Percutaneous Cardiac Interventions","volume":"17","author":"Galli","year":"2024","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention: A consensus document from the Academic Research Consortium for High Bleeding Risk","volume":"40","author":"Urban","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_86","first-page":"441","article-title":"Abbreviated Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in High Bleeding Risk Patients: LEADERS-FREE and ONYX ONE","volume":"9","author":"Price","year":"2020","journal-title":"Interv. Cardiol. Clin."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1056\/NEJMoa1910021","article-title":"Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk","volume":"382","author":"Windecker","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","article-title":"Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk","volume":"373","author":"Urban","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamacardio.2024.3216","article-title":"Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in Patients with Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis","volume":"9","author":"Carvalho","year":"2024","journal-title":"JAMA Cardiol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejim.2024.04.016","article-title":"Consecutive or selectively included high bleeding risk patients in the MASTER DAPT screening log and trial","volume":"126","author":"Landi","year":"2024","journal-title":"Eur. J. Intern. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ahj.2009.01.003","article-title":"Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"157","author":"James","year":"2009","journal-title":"Am. Heart J."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Long, M., Ye, Z., Zheng, J., Chen, W., and Li, L. (2020). Dual anti-platelet therapy following percutaneous coronary intervention in a population of patients with thrombocytopenia at baseline: A meta-analysis. BMC Pharmacol. Toxicol., 21.","DOI":"10.1186\/s40360-020-00409-2"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jacc.2022.11.045","article-title":"Intravascular Imaging During Percutaneous Coronary Intervention: JACC State-of-the-Art Review","volume":"81","author":"Truesdell","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Zhang, W.J., Qiao, X., Guo, W.F., Liang, X.Y., Li, Y., and Wang, Z.L. (2021). Duration of Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome Treated with New Generation Stents: A Meta-Analysis of Randomized Controlled Trials. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.615396"},{"key":"ref_96","first-page":"542","article-title":"Refractory Coronary Stent Thrombosis in a Patient with Chronic Immune Thrombocytopenia on Eltrombopag","volume":"37","author":"Chen","year":"2021","journal-title":"Acta Cardiol. Sin."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1182\/hematology.2020000137","article-title":"Platelet transfusion refractoriness: How do I diagnose and manage?","volume":"2020","author":"Cohn","year":"2020","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/eurheartj\/ehae151","article-title":"Invasive vs. conservative management of older patients with non-ST-elevation acute coronary syndrome: Individual patient data meta-analysis","volume":"45","author":"Kotanidis","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"ytaa577","DOI":"10.1093\/ehjcr\/ytaa577","article-title":"Antiplatelet therapy in patients with acute coronary syndromes and thrombocytopaenia: Awaiting for evidence","volume":"5","author":"Liga","year":"2021","journal-title":"Eur. Heart J. Case Rep."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1111\/jth.14282","article-title":"Laboratory monitoring of P2Y(12) inhibitors: Communication from the SSC of the ISTH","volume":"16","author":"Frelinger","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3171\/2012.9.JNS112286","article-title":"Effect of acetylsalicylic acid usage and platelet transfusion on postoperative hemorrhage and activities of daily living in patients with acute intracerebral hemorrhage","volume":"118","author":"Li","year":"2013","journal-title":"J. Neurosurg."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1161\/CIRCINTERVENTIONS.111.967208","article-title":"Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: The timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study","volume":"5","author":"Mahla","year":"2012","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"E202","DOI":"10.1002\/ccd.26379","article-title":"SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologia intervencionista)","volume":"87","author":"Iliescu","year":"2016","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.tmrv.2004.03.003","article-title":"Relationship between platelet count and bleeding risk in thrombocytopenic patients","volume":"18","author":"Slichter","year":"2004","journal-title":"Transfus. Med. Rev."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.carrev.2021.05.013","article-title":"Antithrombotic Therapy with or without Aspirin after Percutaneous Coronary Intervention or Acute Coronary Syndrome in Patients Taking Oral Anticoagulation: A Meta-Analysis and Network Analysis of Randomized Controlled Trials","volume":"36","author":"Colleran","year":"2022","journal-title":"Cardiovasc. Revasc. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/3\/838\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:37:05Z","timestamp":1759919825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/3\/838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":105,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["jcm14030838"],"URL":"https:\/\/doi.org\/10.3390\/jcm14030838","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]}}}